Trials / Recruiting
RecruitingNCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet in Patients With Advanced Hepatocellular Carcinoma.
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TT-00420 (tinengotinib) | oral |
| DRUG | AK104 | intravenous |
| DRUG | AK112 | intravenous |
Timeline
- Start date
- 2025-07-18
- Primary completion
- 2027-05-10
- Completion
- 2027-12-31
- First posted
- 2025-07-04
- Last updated
- 2026-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07052253. Inclusion in this directory is not an endorsement.